PMV Pharmaceuticals (PMVP)
(Real Time Quote from BATS)
$1.50 USD
0.00 (0.00%)
Updated Oct 2, 2024 10:47 AM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Income Statements
Fiscal Year end for PMV Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 80 | 77 | 58 | 35 | 27 |
Income After Depreciation & Amortization | -80 | -77 | -58 | -35 | -27 |
Non-Operating Income | 11 | 4 | 0 | 1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -69 | -73 | -58 | -34 | -25 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -69 | -73 | -58 | -34 | -25 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -69 | -73 | -58 | -34 | -25 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -84 | -77 | -57 | -34 | -26 |
Depreciation & Amortization (Cash Flow) | -4 | 0 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -80 | -77 | -58 | -35 | -27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 48.02 | 45.60 | 45.14 | 14.37 | NA |
Diluted EPS Before Non-Recurring Items | -1.44 | -1.61 | -1.28 | -2.40 | NA |
Diluted Net EPS (GAAP) | -1.44 | -1.61 | -1.28 | -2.40 | NA |
Fiscal Year end for PMV Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 20.17 | 18.23 | 18.90 | 19.63 | 20.12 |
Income After SG&A, R&D, and Dept/Amort Expenses | -20.17 | -18.23 | -18.90 | -19.63 | -20.12 |
Non-Operating Income | 2.78 | 2.95 | 3.14 | 2.99 | 2.69 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -17.39 | -15.27 | -15.76 | -16.64 | -17.43 |
Income Taxes | -16.17 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.21 | -15.27 | -15.76 | -16.64 | -17.44 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.21 | -15.27 | -15.76 | -16.64 | -17.44 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 51.48 | 51.45 | 50.83 | 49.05 | 45.81 |
Diluted EPS Before Non-Recurring Items | -0.02 | -0.30 | -0.31 | -0.34 | -0.38 |
Diluted Net EPS (GAAP) | -0.02 | -0.30 | -0.30 | -0.34 | -0.38 |